shalini sharp  ultragenyx pharmaceutical inc  zoominfocom shalini sharp  cfo  management  ultragenyx management shalini sharp chief financial officer and executive vice president ms sharp joined ultragenyx in may  as chief financial officer she is responsible for leading the corporate finance strategy and information technology functions and is a member of the company’s executive leadership team ms sharp brings to us nearly twenty years of experience in the life sciences industry ms sharp is a member of the board of directors of agenus inc formerly antigenics inc a publicly traded biotechnology firm where she served as chief financial officer from  to  she joined agenus in  and held increasing roles of responsibility spanning strategic planning corporate development investor relations corporate finance and business development she is also a member of the board of directors of the tb alliance a nonprofit organization dedicated to the development and distribution of treatments for tuberculosis in the developing world prior to agenus ms sharp held similar roles at elan pharmaceuticals from  to  including serving as chief of staff to the chairman of the board of directors during that companys restructuring she has spearheaded numerous financing and business development transactions that were critical to the success of agenus and elan ms sharp was also a management consultant at mckinsey  company as well as an investment banker at goldman sachs specializing in pharmaceuticals and medical devices ms sharp holds both a ba magna cum laude and mba from harvard university about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions privacy policy   ultragenyx pharmaceuticalwebsite design hane chow inc privacy policy sharp electronics  sharpusa join our winning team find your new career with sharp explore the opportunities advanced series color document systems delivering cuttingedge integration and powerful productivity explore find out how this school district is transforming the classroom for the modern learner explore smart fluid and built for impact sharp aquos board® display with a featherlight touch explore super steam tm steam and convection oven the only oven that grills purely with superheated steam explore display share inspire providing the total business experience explore made perfect together sharp carousel  orville redenbacher’s® certified microwave ovens explore microcrave built to matchdesigned to stand out introducing the sharp black stainless steel microwave drawertm explore convenience you can count on userfriendly features make cooking and cleaning easy explore naturally advanced technology for truly clean air explore matcha made easy grinds brews whisks and serves authentic matcha tea in four easy steps explore close hello world keep in touch with news and updates from sharp required required required please enter valid email all fields are required by clicking subscribe you are agreeing to receiving email communication from sharp electronics regarding sharp consumer products your privacy is important to us click here to read our privacy policy close hello world management  ultragenyx pharmaceutical inc management show all emil d kakkis md phd chief executive officer and president dr kakkis is currently ultragenyx’s president and chief executive officer he is also president of the nonprofit everylife foundation for rare diseases an organization he founded in  to work on regulatory policy issues  over the last  years dr kakkis is best known for his work developing novel treatments for rare disorders he began his work developing an enzyme replacement therapy aldurazyme® for the rare disorder mps i with minimal funding and support the struggle to get the therapy translated from a successful canine model to patients succeeded due to the critical financial support of the ryan foundation a patient organization formed by mark and jeanne dant for their son ryan aldurazyme development was later supported by biomarin and genzyme leading to fda approval in  after joining biomarin in  dr kakkis guided the development and approval of two more treatments for rare disorders mps vi and pku and has contributed to the initiation of  other treatment programs for rare disorders three of which are now in clinical development or approved after  years at biomarin dr kakkis funded and launched the everylife foundation for rare diseases a nonprofit foundation dedicated to the acceleration of biotech innovation for rare diseases through practical and scientifically sound improvements to development strategies regulatory policy and law the foundation successfully advocated for improvements to the accelerated approval pathway for rare disease treatments that was passed by congress in fdasia in  dr kakkis went on to found ultragenyx in  to focus on developing as many rare and ultrarare disease therapeutics as possible since its founding ultragenyx has grown to more than  employees developing treatments for five rare and ultrarare diseases in phase  and phase  clinical development   the company went public in january  rare  nasdaq dr kakkis is board certified in both pediatrics and medical genetics he graduated from pomona college magna cum laude and received the vaile prize for his research  he received combined md and phd degrees from the ucla medical scientist program and received the bogen prize for his research he completed a pediatrics residency and medical genetics training fellowship at harbor ucla medical center from  and from  to  was an assistant professor of pediatrics at harborucla medical center where he initiated the enzyme therapy program for mps i  thomas kassberg chief business officer and senior vice president mr kassberg joined ultragenyx in november  he is responsible for leading the companys business development and corporate strategic planning activities as well as the human resources and legal affairs functions mr kassberg brings more than twenty years of experience in the pharmaceutical and biotechnology industries prior to joining ultragenyx mr kassberg worked as an independent consultant in corporate development and business strategy and consulted with a number of companies including corium international inc and ribx pharmaceuticals inc before becoming a consultant mr kassberg worked at proteolix inc where he served as executive vice president of corporate development overseeing business development corporate strategic planning and legal affairs prior to proteolix mr kassberg served as senior vice president of corporate development and commercial operations at intermune inc at intermune he oversaw the commercial team responsible for inline sales of actimmune® and prelaunch planning for latestage products mr kassberg was also a cofounder of plexxikon where he served as vice president business and corporate development in this role he helped to establish the companys initial operations in addition to leading the companys corporate development activities prior to plexxikon mr kassberg served as the senior director of business development and corporate licensing at sugen until the companys acquisition by pharmacia mr kassberg began his career at bristolmyers squibb where he held a variety of positions in strategic planning managed care sales and financial and product analysis he holds an mba from northwestern university and a ba in economics and management from gustavus adolphus college shalini sharp chief financial officer and senior vice president ms sharp joined ultragenyx in may  as chief financial officer and senior vice president she is a member of the senior management team and is responsible for leading the corporate finance function including strategic financial planning accounting budgeting and forecasting financial analysis general risk analysis and financing activities ms sharp is a member of the board of directors of agenus inc formerly antigenics inc a publicly traded biotechnology firm where she served as chief financial officer from  to  she joined agenus in  and held increasing roles of responsibility spanning strategic planning corporate development investor relations corporate finance and business development prior to agenus ms sharp held similar roles at elan pharmaceuticals from  to  including serving as chief of staff to the chairman of the board of directors during that companys restructing with  years of industry experience ms sharp has spearheaded numerous financing and business development transactions that have been critical to the success of agenus and elan  prior to elan ms sharp was a management consultant at mckinsey  company as well as an investment banker at goldman sachs specializing in pharmaceuticals and medical devices ms sharp holds both a ba magna cum laude and mba from harvard university sunil agarwal md chief medical officer and senior vice president sunil agarwal md joined ultragenyx as chief medical officer in august  prior to ultragenyx dr agarwal served in various leadership capacities at genentech for  years most recently he held the position of senior vice president and global head of clinical development for omni ophthalmology metabolism neurosciences immunology and infectious diseases since january  prior to that dr agarwal held the positions of senior vp for immunology and infectious diseases and vp for rheumatology from july  to december  he also held the position of vp of genentech drug safety from january  to july  from september  to january  dr agarwal held positions of increasing responsibility in genentech’s immunology clinical organization and was involved in the development oversight of multiple molecules including raptiva rituxan and ocrelizumab before joining genentech dr agarwal was at medimmune and guilford pharmaceuticals where he worked in both development and medical affairs and led the formation of the medical affairs organization for guilford dr agarwal obtained his bachelor of science in neurobiology at cornell university and then earned his medical degree from tufts university school of medicine he completed his residency at children’s national medical center cnmc washington dc and subsequently joined the facility at george washington university school of medicine as an assistant clinical professor of pediatrics he practiced in the pediatric emergency department at cnmc dennis huang chief technical operations officer and senior vice president dennis huang joined ultragenyx in may  he will be responsible for the short and long term strategy and development plans for manufacturing and supply chain distribution of all ultragenyx products from inception to commercialization as well as manage all aspects of clinical and commercial manufacturing operations and provide leadership and direction to the technical operations team    most recently dennis was the senior vice president of manufacturing and supply chain for intermune incorporated from  to  where he led the global manufacturing organization and supply chain activities for the company prior to intermune dennis served as the vice president of biologics manufacturing and development for allergan inc during his year tenure at allergan he improved the commercial manufacturing performance and expanded the biologics development capability which resulted in a rapid expansion of the biologics pipeline earlier in his career dennis held several positions at novartis ag formerly chiron inc at genentech inc and at synergen currently amgen where he worked in a number of roles including manufacturing quality and process development dennis holds a ba in chemistry from knox college in galesburg ilinois john ditton vice president commerical planning mr ditton brings over  years of senior management background in strategic marketing and new product planning with strong operational and sales knowledge developed as a leader of commercial teams in healthcare rare diseases pharmaceutical and medical device marketing he has led successful us and row orphan product launches in addition to serving in leadership roles with respect to marketing campaigns for largemarket pharmaceutical products mr ditton joined ultragenyx in april  and is responsible for commercial planning for pipeline products at the company mr ditton was most recently the chief operating officer at everylife foundation for rare diseases a position he held from  to  prior to everylife foundation he served as the vice president of marketing at diamics from  to  director of global marketing at biomarin pharmaceutical from  to  senior product manager at merckdey from  to  and business development manager at health plan of the redwoods from  to  cordelia leonard rac vice president regulatory affairs ms leonard heads up the company’s regulatory affairs department whose members collectively have over  years of regulatory experience working with the fda ema pmda and other worldwide regulatory agencies approximately twenty of those  years she and her team spent working to develop drugs for orphan indications at biomarin pharmaceutical during her  year tenure at biomarin ms leonard started up and led the cmc regulatory group then transferred to the clinicalnonclinical regulatory group where she advanced to lead that group as well she was involved in securing various global approvals for aldurazyme naglazyme kuvan and orapred opt prior to biomarin ms leonard worked in regulatory for  years at cerus corporation on drugdevice combination products in protein purification and analytical chemistry at boehringer mannheim and in carbohydrate chemistry at genentech ms leonard received bachelor degrees in chemistry and biological science from the university of california irvine and holds both us and eu regulatory affairs certifications vimal srivastava vice president program development with more than  years of project and portfolio management experience from research to commercialization stage programs mr srivastava joined ultragenyx in august  and serves as vice president program development overseeing the program development activities for the company mr srivastava’s experience and background includes over  years in the pharmaceutical and biotechnology industry specifically focused on drug development in neurosciences and metabolic disorders including rare genetic disorders before joining ultragenyx mr srivastava was senior director portfolio and project management at elanjanssen alzheimer immunotherapy a position he held from  until  he was also director global program manager diabetes at amgen from  to  and director program management at biomarin pharmaceutical from  to  mr srivastava holds a bs in pharmacy from banaras hindu university a ms in medicinal chemistry from st johns university and a mas in management from johns hopkins university michael vellard phd vice president research dr vellard joined ultragenyx as vice president research in may  prior to joining ultragenyx dr vellard worked as head of lysosomal biology at biomarin pharmaceutical inc a biopharmaceutical company from october  to may  he was a postdoctoral fellow in the pediatric department at ucla harbor medical center from september  to june  dr vellard received his bs in natural and life sciences and ms in molecular and cellular genetics from the university of lyon i france  he obtained his phd in virology from the  pasteur and curie institutes universities paris vi vii and xi france antonis koutsoukos phd vice president biometrics dr koutsoukos joined ultragenyx as our vice president of biometrics in october  he is responsible for leading the biostatistics statistical programming and data management functions for the company prior to ultragenyx mr koutsoukos worked as vice president of biometrics at allos therapeutics a biopharmaceutical company from september  to march  which was acquired by spectrum pharmaceuticals he was also director of biostatistics at amgen inc a biotechnology company from may  to september  prior to amgen mr koutsoukos spent  years at quintiles as a director of biostatistics his experience also includes  years at the fda center for drugs evaluation and research cder division and about  years at the national cancer institute biometric research branch ctep dct mr koutsoukos received his phd and ma both in mathematical statistics from the university of maryland college park javier san martin md vice president clinical development dr san martin has served as our vice president clinical development since december  prior to ultragenyx dr san martin served as senior vice president of clinical development at alder biopharmaceuticals inc a pharmaceutical company from january  through may  prior to alder dr san martin served as executive director and global development leader at amgen inc a biotechnology company from march  to september  prior to amgen dr san martin served as medical advisor at eli lilly and company a pharmaceutical company from june  to february  dr san martin received his md from the university of buenos aires medical school and completed his residence in internal medicine at cemic university of buenos aires investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us shareholder tools briefcase email alerts print share facebook google linkedin twitter email rss about pipeline for patients investors careers partnering contact about pipeline for patients investors careers partnering contact   ultragenyx pharmaceuticals website design hane chow inc privacy policy shalini sharp joins array biopharma board of directors employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       shalini sharp joins array biopharma arry board of directors tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs boulder colo april   prnewswire  array biopharma inc nasdaq arry today announced that shalini sharp chief financial officer and executive vice president of ultragenyx pharmaceutical inc joined the companys board of directors effective april   ms sharp has been appointed to the audit committee of the board   ms sharp has served as chief financial officer of ultragenyx a biopharmaceutical company focused on rare diseases since  where she is responsible for leading the corporate finance strategy and information technology functions and is a member of the companys executive leadership team ms sharp brings nearly  years of experience in the life sciences industryron squarer chief executive officer of array noted shalini has an ideal background to complement the expertise of our board of directors  her financial leadership at healthcare organizations will be invaluable as we focus our efforts in oncology and prepare for commercializationms sharp added array has built an impressive development pipeline of therapeutics that is advancing in latestage clinical trials and provides the opportunity to significantly benefit patients in areas of unmet need  im excited to join the companys board at such an important time in its history as it nears commercialization of its drugs i look forward to working with ron and my fellow board members through this important evolution of arrayms sharp is also a member of the board of directors of agenus inc formerly antigenics inc a publicly traded immunooncology company where she served as chief financial officer from  to  she joined agenus in  and held increasing roles of responsibility spanning strategic planning corporate development investor relations corporate finance and business development she is also a member of the board of directors of the tb alliance a nonprofit organization dedicated to the development and distribution of treatments for tuberculosis in the developing world prior to agenus ms sharp held similar roles at elan pharmaceuticals from  to  including serving as chief of staff to the chairman of the board of directors during that companys restructuring she has spearheaded numerous financing and business development transactions that were critical to the success of agenus and elan ms sharp was also a management consultant at mckinsey  company as well as an investment banker at goldman sachs specializing in pharmaceuticals and medical devices  ms sharp holds both a ba magna cum laude and a mba from harvard universityms sharp will serve as a class ii director on the board with a term that expires at the annual meeting of arrays stockholders in  about array biopharma array biopharma inc is a biopharmaceutical company focused on the discovery development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer seven registration studies are currently advancing related to seven drugs binimetinib mek encorafenib lgx selumetinib partnered with astrazeneca danoprevir partnered with roche larotrectinib partnered with loxo oncology tucatinib partnered with cascadian therapeutics and ipatasertib partnered with rocheforwardlooking statementthis press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  including statements about the potential for commercialization of arrays products and the expected contributions of ms sharp to the board of directors these statements involve significant risks and uncertainties including those discussed in our most recent annual report filed on form k in our quarterly reports filed on form q and in other reports filed by array with the securities and exchange commission because these statements reflect our current expectations concerning future events our actual results could differ materially from those anticipated in these forwardlooking statements as a result of many factors these factors include but are not limited to our ability to continue to fund and successfully progress internal research and development efforts and to create effective commercially viable drugs risks associated with our dependence on our collaborators for the clinical development and commercialization of our outlicensed drug candidates the ability of our collaborators and of array biopharma inc to meet objectives tied to milestones and royalties our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials risks associated with our dependence on thirdparty service providers to successfully conduct clinical trials within and outside the united states our ability to achieve and maintain profitability and maintain sufficient cash resources the extent to which the pharmaceutical and biotechnology industries are willing to inlicense drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities our ability to outlicense our proprietary candidates on favorable terms and our ability to attract and retain experienced scientists and management we are providing this information as of april   we undertake no duty to update any forwardlooking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statementscontact tricia haugeto                             thaugetoarraybiopharmacom to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesshalinisharpjoinsarraybiopharmaboardofdirectorshtmlsource array biopharma inc read at biospacecom related news array biopharma arry withdraws skin cancer nda for binimetinib senate committee approves scott gottlieb for top fda job array biopharma arry has a potential blockbuster melanoma drug on its hands the billionaire and the drug pricefixing scandal array biopharma arry reports financial results for the second quarter of fiscal  ma speculation begins as sarepta srpt ceo puts in his notice array biopharma arry to report financial results for the second quarter of fiscal  on february   gilead gilds rumored ma target incyte incy doubled ceos pay package in  pierre fabre and array biopharma arry release columbus phase  study results in brafmutant melanoma presented at society for melanoma research annual congress men still hold  out of  life science director positions please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • array biopharma inc   • biotechpharma  personnel                 shalini sharp joins array biopharma board of directors shalini sharp joins array biopharma board of directors industry veteran brings strong financial expertise news provided by array biopharma inc apr    et share this article boulder colo april   prnewswire  array biopharma inc nasdaq arry today announced that shalini sharp chief financial officer and executive vice president of ultragenyx pharmaceutical inc joined the companys board of directors effective april   ms sharp has been appointed to the audit committee of the board    shalini sharp array biopharma board of directors ms sharp has served as chief financial officer of ultragenyx a biopharmaceutical company focused on rare diseases since  where she is responsible for leading the corporate finance strategy and information technology functions and is a member of the companys executive leadership team ms sharp brings nearly  years of experience in the life sciences industry ron squarer chief executive officer of array noted shalini has an ideal background to complement the expertise of our board of directors  her financial leadership at healthcare organizations will be invaluable as we focus our efforts in oncology and prepare for commercialization ms sharp added array has built an impressive development pipeline of therapeutics that is advancing in latestage clinical trials and provides the opportunity to significantly benefit patients in areas of unmet need  im excited to join the companys board at such an important time in its history as it nears commercialization of its drugs i look forward to working with ron and my fellow board members through this important evolution of array ms sharp is also a member of the board of directors of agenus inc formerly antigenics inc a publicly traded immunooncology company where she served as chief financial officer from  to  she joined agenus in  and held increasing roles of responsibility spanning strategic planning corporate development investor relations corporate finance and business development she is also a member of the board of directors of the tb alliance a nonprofit organization dedicated to the development and distribution of treatments for tuberculosis in the developing world prior to agenus ms sharp held similar roles at elan pharmaceuticals from  to  including serving as chief of staff to the chairman of the board of directors during that companys restructuring she has spearheaded numerous financing and business development transactions that were critical to the success of agenus and elan ms sharp was also a management consultant at mckinsey  company as well as an investment banker at goldman sachs specializing in pharmaceuticals and medical devices  ms sharp holds both a ba magna cum laude and a mba from harvard university ms sharp will serve as a class ii director on the board with a term that expires at the annual meeting of arrays stockholders in  about array biopharma array biopharma inc is a biopharmaceutical company focused on the discovery development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer seven registration studies are currently advancing related to seven drugs binimetinib mek encorafenib lgx selumetinib partnered with astrazeneca danoprevir partnered with roche larotrectinib partnered with loxo oncology tucatinib partnered with cascadian therapeutics and ipatasertib partnered with roche forwardlooking statementthis press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  including statements about the potential for commercialization of arrays products and the expected contributions of ms sharp to the board of directors these statements involve significant risks and uncertainties including those discussed in our most recent annual report filed on form k in our quarterly reports filed on form q and in other reports filed by array with the securities and exchange commission because these statements reflect our current expectations concerning future events our actual results could differ materially from those anticipated in these forwardlooking statements as a result of many factors these factors include but are not limited to our ability to continue to fund and successfully progress internal research and development efforts and to create effective commercially viable drugs risks associated with our dependence on our collaborators for the clinical development and commercialization of our outlicensed drug candidates the ability of our collaborators and of array biopharma inc to meet objectives tied to milestones and royalties our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials risks associated with our dependence on thirdparty service providers to successfully conduct clinical trials within and outside the united states our ability to achieve and maintain profitability and maintain sufficient cash resources the extent to which the pharmaceutical and biotechnology industries are willing to inlicense drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities our ability to outlicense our proprietary candidates on favorable terms and our ability to attract and retain experienced scientists and management we are providing this information as of april   we undertake no duty to update any forwardlooking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements contact tricia haugeto                             thaugetoarraybiopharmacom   to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesshalinisharpjoinsarraybiopharmaboardofdirectorshtml source array biopharma inc related links httpwwwarraybiopharmacom jun    et preview array biopharma to present at the goldman sachs th annual global healthcare conference mar    et preview array biopharma provides nemo update my news release contains wide tables view fullscreen also from this source jun    et array biopharma to present at the goldman sachs th annual mar    et array biopharma provides nemo update explore more news releases in similar topics biotechnology health care  hospitals medical pharmaceuticals pharmaceuticals personnel announcements you just read shalini sharp joins array biopharma board of directors news provided by array biopharma inc apr    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search shalini sharp joins array biopharma board of directors  marketwatch bulletin investor alert new york markets close in market snapshot winners and losers press release april    pm edt shalini sharp joins array biopharma board of directors industry veteran brings strong financial expertise boulder colo april   prnewswire  array biopharma inc quoteszigmancomposite arry  today announced that shalini sharp chief financial officer and executive vice president of ultragenyx pharmaceutical inc joined the companys board of directors effective april   ms sharp has been appointed to the audit committee of the board    ms sharp has served as chief financial officer of ultragenyx a biopharmaceutical company focused on rare diseases since  where she is responsible for leading the corporate finance strategy and information technology functions and is a member of the companys executive leadership team ms sharp brings nearly  years of experience in the life sciences industry ron squarer chief executive officer of array noted shalini has an ideal background to complement the expertise of our board of directors  her financial leadership at healthcare organizations will be invaluable as we focus our efforts in oncology and prepare for commercialization ms sharp added array has built an impressive development pipeline of therapeutics that is advancing in latestage clinical trials and provides the opportunity to significantly benefit patients in areas of unmet need  im excited to join the companys board at such an important time in its history as it nears commercialization of its drugs i look forward to working with ron and my fellow board members through this important evolution of array ms sharp is also a member of the board of directors of agenus inc formerly antigenics inc a publicly traded immunooncology company where she served as chief financial officer from  to  she joined agenus in  and held increasing roles of responsibility spanning strategic planning corporate development investor relations corporate finance and business development she is also a member of the board of directors of the tb alliance a nonprofit organization dedicated to the development and distribution of treatments for tuberculosis in the developing world prior to agenus ms sharp held similar roles at elan pharmaceuticals from  to  including serving as chief of staff to the chairman of the board of directors during that companys restructuring she has spearheaded numerous financing and business development transactions that were critical to the success of agenus and elan ms sharp was also a management consultant at mckinsey  company as well as an investment banker at goldman sachs specializing in pharmaceuticals and medical devices  ms sharp holds both a ba magna cum laude and a mba from harvard university ms sharp will serve as a class ii director on the board with a term that expires at the annual meeting of arrays stockholders in  about array biopharma array biopharma inc is a biopharmaceutical company focused on the discovery development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer seven registration studies are currently advancing related to seven drugs binimetinib mek encorafenib lgx selumetinib partnered with astrazeneca danoprevir partnered with roche larotrectinib partnered with loxo oncology tucatinib partnered with cascadian therapeutics and ipatasertib partnered with roche forwardlooking statement this press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  including statements about the potential for commercialization of arrays products and the expected contributions of ms sharp to the board of directors these statements involve significant risks and uncertainties including those discussed in our most recent annual report filed on form k in our quarterly reports filed on form q and in other reports filed by array with the securities and exchange commission because these statements reflect our current expectations concerning future events our actual results could differ materially from those anticipated in these forwardlooking statements as a result of many factors these factors include but are not limited to our ability to continue to fund and successfully progress internal research and development efforts and to create effective commercially viable drugs risks associated with our dependence on our collaborators for the clinical development and commercialization of our outlicensed drug candidates the ability of our collaborators and of array biopharma inc to meet objectives tied to milestones and royalties our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials risks associated with our dependence on thirdparty service providers to successfully conduct clinical trials within and outside the united states our ability to achieve and maintain profitability and maintain sufficient cash resources the extent to which the pharmaceutical and biotechnology industries are willing to inlicense drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities our ability to outlicense our proprietary candidates on favorable terms and our ability to attract and retain experienced scientists and management we are providing this information as of april   we undertake no duty to update any forwardlooking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements contact tricia haugeto                             thaugetoarraybiopharmacom   to view the original version on pr newswire visit httpwwwprnewswirecomnewsreleasesshalinisharpjoinsarraybiopharmaboardofdirectorshtml source array biopharma inc copyright c  pr newswire all rights reserved quoteszigmancomposite add to watchlist arry array biopharma inc us  us nasdaq     volume m july   p pe rationa dividend yieldna market cap billion rev per employee most popular  all the companies in jeff bezos’s empire in one large chart  market snapshot stock market lower after amazon disappointment but pares losses  the ratings game get ready for the lessprofitable amazon that you used to know  marketwatch first take intel earnings have message for amd and nvidia ‘bring it on’  sectorwatch why  million americans have no bank account not what you think find a broker partner center » featured stories seeing america again through new eyes how to dig yourself out of debt move over tesla karma unveils its hybrid sports car the salary you need to afford a home in these  cities why opec will never cut production again log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest poil logs its biggest weekly gain of the year pcan christopher nolan’s ‘dunkirk’ crack china’s market pwhy john mccain ignored trump plea and shot down obamacare repeal pwall street isn’t ready for a point tumble in the dow industrials pus economy speeds up in second quarter after bumpy ride earlier in the year pwaters has testy exchange with mnuchin over trump financing ptreasury yields slide after secondquarter gdp data pinvestment chief who manages  billion sees big gains on the ‘frontier’ pthese companies spent over  billion buying back shares while their ceos were dumping them pthis fund strategist says there’s at least one way companies can survive amazon’s onslaught pweekend roundup amazon’s spending  surviving amazon  caterpillar’s comeback pwhat the proposed  cut in farm subsidies mean for your grocery bill phealthcare fund managers say a spike in drugs and devices will produce big returns pcorrectedgoodyear stock stumbles  after quarter ‘played out differently than we expected’ pwhat  million simulations tell us about president trump’s chances of achieving  economic growth ppeople still aren’t saving for retirement — and that’s part of why myra is shutting down pto be a better investor read more good novels pact like a pro athlete the next time you ask for a pay raise pwhy gold buyers are so susceptible to fraud poil prices log biggest weekly gain of the year loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  shalini sharp ultragenyx pharmaceutical inc profile  biography  bloomberg feedback shalini sharp exec vpcfo ultragenyx pharmaceutical inc career history exec vpcfo ultragenyx pharmaceutical inc present vpcfo agenus inc  vpcfo antigenics inc  antigenics inc  agenus inc  elan pharmaceuticals inc  senior vpfinancecfo ultragenyx pharmaceutical inc unknown dirstrategic planning elan corp plc former management consultant mckinsey  co former investment banker goldman sachs former show more website wwwultragenyxcom corporate information address  leveroni court novato ca  united states phone  fax  web url wwwultragenyxcom from the web personal information education president  fellows of harvard college bachelors degree president  fellows of harvard college masters degree business administration memberships board memberships array biopharma inc board member present agenus inc board member present other memberships tb alliance board member sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft shalini sharp joins array biopharma board of directorshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets close in  minssp  dow  nasdaq todays chartsdont get blindsided by teslas shiny new model shalini sharp joins array biopharma board of directorspr newswireapril  reblogsharetweetshareboulder colo april   prnewswire  array biopharma inc arry today announced that shalini sharp chief financial officer and executive vice president of ultragenyx pharmaceutical inc joined the companys board of directors effective april   ms sharp has been appointed to the audit committee of the board   view photosms sharp has served as chief financial officer of ultragenyx a biopharmaceutical company focused on rare diseases since  where she is responsible for leading the corporate finance strategy and information technology functions and is a member of the companys executive leadership team ms sharp brings nearly  years of experience in the life sciences industryron squarer chief executive officer of array noted shalini has an ideal background to complement the expertise of our board of directors  her financial leadership at healthcare organizations will be invaluable as we focus our efforts in oncology and prepare for commercializationms sharp added array has built an impressive development pipeline of therapeutics that is advancing in latestage clinical trials and provides the opportunity to significantly benefit patients in areas of unmet need  im excited to join the companys board at such an important time in its history as it nears commercialization of its drugs i look forward to working with ron and my fellow board members through this important evolution of arrayms sharp is also a member of the board of directors of agenus inc formerly antigenics inc a publicly traded immunooncology company where she served as chief financial officer from  to  she joined agenus in  and held increasing roles of responsibility spanning strategic planning corporate development investor relations corporate finance and business development she is also a member of the board of directors of the tb alliance a nonprofit organization dedicated to the development and distribution of treatments for tuberculosis in the developing world prior to agenus ms sharp held similar roles at elan pharmaceuticals from  to  including serving as chief of staff to the chairman of the board of directors during that companys restructuring she has spearheaded numerous financing and business development transactions that were critical to the success of agenus and elan ms sharp was also a management consultant at mckinsey  company as well as an investment banker at goldman sachs specializing in pharmaceuticals and medical devices  ms sharp holds both a ba magna cum laude and a mba from harvard universityms sharp will serve as a class ii director on the board with a term that expires at the annual meeting of arrays stockholders in about array biopharma array biopharma inc is a biopharmaceutical company focused on the discovery development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer seven registration studies are currently advancing related to seven drugs binimetinib mek encorafenib lgx selumetinib partnered with astrazeneca danoprevir partnered with roche larotrectinib partnered with loxo oncology tucatinib partnered with cascadian therapeutics and ipatasertib partnered with rocheread moreforwardlooking statementthis press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  including statements about the potential for commercialization of arrays products and the expected contributions of ms sharp to the board of directors these statements involve significant risks and uncertainties including those discussed in our most recent annual report filed on form k in our quarterly reports filed on form q and in other reports filed by array with the securities and exchange commission because these statements reflect our current expectations concerning future events our actual results could differ materially from those anticipated in these forwardlooking statements as a result of many factors these factors include but are not limited to our ability to continue to fund and successfully progress internal research and development efforts and to create effective commercially viable drugs risks associated with our dependence on our collaborators for the clinical development and commercialization of our outlicensed drug candidates the ability of our collaborators and of array biopharma inc to meet objectives tied to milestones and royalties our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials risks associated with our dependence on thirdparty service providers to successfully conduct clinical trials within and outside the united states our ability to achieve and maintain profitability and maintain sufficient cash resources the extent to which the pharmaceutical and biotechnology industries are willing to inlicense drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities our ability to outlicense our proprietary candidates on favorable terms and our ability to attract and retain experienced scientists and management we are providing this information as of april   we undertake no duty to update any forwardlooking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements contact tricia haugeto                             thaugetoarraybiopharmacom  view photosto view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesshalinisharpjoinsarraybiopharmaboardofdirectorshtmlreblogsharetweetsharerecently viewedyour list is emptywhat to read nextverizon soars on beat starbucks big china deal astrazeneca sinks as drug trial disappointsyahoo financethis will be in everyones household by banyan hillsponsoredwind projects in peril as indian states rethink purchasesbloombergamazon surpasses b mark bezos briefly becomes the world’s richest personinvestopediashares in astrazeneca dive as key cancer drug trial failsassociated presszuckerberg wifes ambitious secret finally exposedunewzmesponsoredmeg whitman rules out becoming uber ceo reaffirms commitment to hpecnbcthe real reason overseas manufacturing is coming to americayahoo financethe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderengineer finds pattern makes millions in stocksmoney morningsponsoredtodays charts dont get blindsided by teslas shiny new model yahoo financechevron and exxon mobil have a tough path ahead nyse traderyahoo finance videohow a oneofakind business has kept  kitchens out of landfillsyahoo financediscover it  out of  avg by k customersdiscover cardsponsoredtax cuts just got more likelyyahoo financethe  most profitable markets for home sellerscreditcommcconnell lashes out at gop defectors democrats in aftermath of disappointing health care voteliberaltroll mcconnell is a petty power hungry little man that got the defeat he so richly deservesjoin the conversation  k